Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., formerly known as Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHC), is a clinical-stage biopharmaceutical company that completed a de-SPAC business combination in 2022. The blank check company was sponsored by Amplitude Healthcare and raised capital through a 2021 IPO targeting the healthcare sector, specifically opportunities in hematopoietic stem cell biology and transplant conditioning therapies. Following the merger, the combined entity operates under the Jasper Therapeutics name, advancing its lead asset, JSP191, a monoclonal antibody designed to enable safer bone marrow transplants. The company filed an 8-K with the SEC on August 14, 2026, under accession number 0001213900-26-090055. For comprehensive filing history, deal terms, sponsor details, and real-time SPAC intelligence on AMHC and thousands of other transactions, create a free account at SpacDesk.